Effect of Adalimumab on Peripheral Blood Mononuclear Cells in Non-Infectious Uveitis.

Abstract

PURPOSE:

This study analyzed the effect of adalimumab on peripheral blood mononuclear cells (PBMCs) in uveitis.

METHODS:

PBMCs and serum S100A12 levels from 14 uveitis patients and 28 healthy controls were analyzed. Patient samples were taken before (w0), and 6 (w6) and 12 (w12) weeks after initiation of adalimumab therapy.

RESULTS:

Monocytes expressing CD124, CD86, CD39, CD115, and MHCII were decreased in patients. Adalimumab induced CD86+ and CD39+ monocytes, and further decreased the frequency of MHCII- and CD124-positive cells. Patients (w0) had increased percentages of Th1-, Th17-, and Th2 cells and T cell subsets showed a pro-inflammatory polarization (p = 0.02 ratio Th17/Treg patients w0 vs controls), which was reduced upon adalimumab treatment (p = 0.05 w0 vs w6). S100A12 levels were increased in patients (p = 0.02) and reduced under treatment (p = 0.02 for w6/w12).

CONCLUSIONS:

The phenotype of PBMCs from uveitis patients is modified upon adalimumab treatment. Serum S100A12 levels reflect the systemic immune response.

• Authors: Karoline Walscheid, Toni Weinhage, Dirk Foell, Carsten Heinz, Maren Kasper, Arnd Heiligenhaus
• Journal: Ocular immunology and inflammation (Ocul Immunol Inflamm) Vol. 27 Issue 2 Pg. 330-337 ( 2019) ISSN: 1744-5078 [Electronic] England
• PMID: 29020495 (Publication Type: Journal Article)

Chemical References

• Anti-Inflammatory Agents
• Adalimumab

Topics

• Adalimumab (administration & dosage)
• Adolescent
• Anti-Inflammatory Agents (administration & dosage)
• Child
• Child, Preschool
• Dose-Response Relationship, Drug
• Female
• Humans
• Leukocytes, Mononuclear (drug effects, immunology, pathology)
• Male
• Monocytes (drug effects, immunology, pathology)
• Retrospective Studies
• T-Lymphocytes, Regulatory (drug effects, immunology, pathology)
• Treatment Outcome
• Uveitis (blood, drug therapy, immunology)